These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 18068041)

  • 1. Regression of atherosclerosis with therapeutic antibodies pipe cleaner or pipe dream?
    Ginsburg GS
    J Am Coll Cardiol; 2007 Dec; 50(24):2319-21. PubMed ID: 18068041
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice.
    Schiopu A; Frendéus B; Jansson B; Söderberg I; Ljungcrantz I; Araya Z; Shah PK; Carlsson R; Nilsson J; Fredrikson GN
    J Am Coll Cardiol; 2007 Dec; 50(24):2313-8. PubMed ID: 18068040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.
    Schiopu A; Bengtsson J; Söderberg I; Janciauskiene S; Lindgren S; Ares MP; Shah PK; Carlsson R; Nilsson J; Fredrikson GN
    Circulation; 2004 Oct; 110(14):2047-52. PubMed ID: 15451805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis.
    Thota LN; Ponnusamy T; Lu X; Mundkur L
    Cardiovasc Drugs Ther; 2019 Aug; 33(4):385-398. PubMed ID: 31332656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100.
    Ström A; Fredrikson GN; Schiopu A; Ljungcrantz I; Söderberg I; Jansson B; Carlsson R; Hultgårdh-Nilsson A; Nilsson J
    Atherosclerosis; 2007 Feb; 190(2):298-305. PubMed ID: 16677655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies.
    Fredrikson GN; Björkbacka H; Söderberg I; Ljungcrantz I; Nilsson J
    J Intern Med; 2008 Dec; 264(6):563-70. PubMed ID: 18783480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease.
    Nilsson J; Nordin Fredrikson G; Schiopu A; Shah PK; Jansson B; Carlsson R
    Curr Pharm Des; 2007; 13(10):1021-30. PubMed ID: 17430165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE
    Dunér P; Mattisson IY; Fogelstrand P; Glise L; Ruiz S; Farina C; Borén J; Nilsson J; Bengtsson E
    Sci Rep; 2021 Apr; 11(1):9022. PubMed ID: 33907226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers.
    Gonçalves I; Cherfan P; Söderberg I; Nordin Fredrikson G; Jonasson L
    Autoimmunity; 2009 Mar; 42(3):203-8. PubMed ID: 19301201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction.
    Sjögren P; Fredrikson GN; Samnegard A; Ericsson CG; Ohrvik J; Fisher RM; Nilsson J; Hamsten A
    Eur Heart J; 2008 Sep; 29(18):2218-26. PubMed ID: 18664466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherosclerosis in developing and developed countries: relation with immune dysregulation and hygiene hypothesis.
    Clerc G
    Med Hypotheses; 2006; 66(1):209-10. PubMed ID: 16216436
    [No Abstract]   [Full Text] [Related]  

  • 12. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease.
    Soto Y; Conde H; Aroche R; Brito V; Luaces P; Nasiff A; Obregón A; Vázquez López AM
    Hum Antibodies; 2009; 18(3):109-17. PubMed ID: 19729805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies against modified apolipoprotein B-100 in relation to low-density lipoprotein size and the metabolic syndrome in otherwise healthy men.
    Sjögren P; Fredrikson GN; Rosell M; de Faire U; Hamsten A; Nilsson J; Hellenius ML; Fisher RM
    Metabolism; 2008 Mar; 57(3):362-6. PubMed ID: 18249208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis.
    Ishigaki Y; Katagiri H; Gao J; Yamada T; Imai J; Uno K; Hasegawa Y; Kaneko K; Ogihara T; Ishihara H; Sato Y; Takikawa K; Nishimichi N; Matsuda H; Sawamura T; Oka Y
    Circulation; 2008 Jul; 118(1):75-83. PubMed ID: 18559699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained response to etanercept after failing infliximab, in a patient with relapsing polychondritis with tracheomalacia.
    Subrahmanyam P; Balakrishnan C; Dasgupta B
    Scand J Rheumatol; 2008; 37(3):239-40. PubMed ID: 18465465
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid response of nail psoriasis to etanercept.
    Rallis E; Stavropoulou E; Rigopoulos D; Verros C
    J Rheumatol; 2008 Mar; 35(3):544-5. PubMed ID: 18322982
    [No Abstract]   [Full Text] [Related]  

  • 17. Nasal immunization with heat shock protein 65 attenuates atherosclerosis and reduces serum lipids in cholesterol-fed wild-type rabbits probably through different mechanisms.
    Xiong Q; Li J; Jin L; Liu J; Li T
    Immunol Lett; 2009 Jun; 125(1):40-5. PubMed ID: 19505506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.
    Sasaki N; Yamashita T; Takeda M; Shinohara M; Nakajima K; Tawa H; Usui T; Hirata K
    Circulation; 2009 Nov; 120(20):1996-2005. PubMed ID: 19884470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice.
    Shiraishi Y; Watanabe T; Suguro T; Nagashima M; Kato R; Hongo S; Itabe H; Miyazaki A; Hirano T; Adachi M
    J Hypertens; 2008 Oct; 26(10):1955-65. PubMed ID: 18806619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
    Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
    Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.